Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
Cell Reports. Medicine
|
September 18, 2024
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, et al.
BMJ Open
|
April 29, 2022
A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial
Eleanor M Hudson, Samantha Noutch, Sarah Brown, et al.
The Journal of Pathology. Clinical Research
|
May 14, 2020
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
Antonia K Roseweir, James H Park, Sanne Ten Hoorn, et al.
Astrobiology
|
February 15, 2019
Biological Contamination Prevention for Outer Solar System Moons of Astrobiological Interest: What Do We Need to Know?
Petra Rettberg, André Antunes, John Brucato, et al.
Nucleic Acids Research
|
February 5, 2026
AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs
Zijian Zhang, Zornitsa Vasileva Kotopanova, Kexin Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Radiation Oncology (London, England)
|
December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)
|
August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Nature Communications
|
August 1, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial
Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
Cell Reports. Medicine
|
September 18, 2024
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, et al.
BMJ Open
|
April 29, 2022
A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial
Eleanor M Hudson, Samantha Noutch, Sarah Brown, et al.
The Journal of Pathology. Clinical Research
|
May 14, 2020
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
Antonia K Roseweir, James H Park, Sanne Ten Hoorn, et al.
Astrobiology
|
February 15, 2019
Biological Contamination Prevention for Outer Solar System Moons of Astrobiological Interest: What Do We Need to Know?
Petra Rettberg, André Antunes, John Brucato, et al.
Nucleic Acids Research
|
February 5, 2026
AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs
Zijian Zhang, Zornitsa Vasileva Kotopanova, Kexin Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Radiation Oncology (London, England)
|
December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)
|
August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Nature Communications
|
August 1, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial
Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Page
of 9